UbiVac

Bristol Myers Squibb, UbiVac to assess combination immunotherapy for advanced triple-negative breast cancer
Pharmaceutical Business Review
Wed, 06/10/20 - 10:54 am
UbiVac
Bristol-Myers Squibb
clinical trials
triple negative breast cancer
DPV-001